Technical Analysis for SLS - SELLAS Life Sciences Group, Inc.

Grade Last Price % Change Price Change
C 1.19 0.85% 0.01
SLS closed up 0.85 percent on Friday, November 1, 2024, on approximately normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
Earnings due: Nov 7
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Down Up

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Gapped Down Weakness 0.00%
20 DMA Resistance Bearish 0.85%
Fell Below 200 DMA Bearish 0.85%
MACD Bearish Signal Line Cross Bearish 0.85%
Fell Below 20 DMA Bearish 0.00%
200 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.25%
20 DMA Support Bullish -3.25%

   Recent Intraday Alerts

Alert Time
20 DMA Resistance about 19 hours ago
Rose Above 20 DMA about 19 hours ago
Up 2% about 19 hours ago
Up 1% about 20 hours ago
Reversed from Down about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

SELLAS Life Sciences Group, Inc. Description

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Solid Tumors Cancer Treatment Oncology Breast Cancer Acute Myeloid Leukemia Immunotherapies Antineoplastic Drugs Ovarian Cancer Treatment Of Breast Cancer Hematologic Malignancies Oncolytics Biotech Treatment Of Acute Myeloid Leukemia Novel Cancer Endometrial Cancer Pembrolizumab Gynaecological Cancer Gynaecology Ovarian And Endometrial Cancers

Is SLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.72
52 Week Low 0.4986
Average Volume 506,489
200-Day Moving Average 1.18
50-Day Moving Average 1.24
20-Day Moving Average 1.21
10-Day Moving Average 1.18
Average True Range 0.07
RSI (14) 47.09
ADX 22.31
+DI 16.54
-DI 27.36
Chandelier Exit (Long, 3 ATRs) 1.11
Chandelier Exit (Short, 3 ATRs) 1.27
Upper Bollinger Bands 1.29
Lower Bollinger Band 1.12
Percent B (%b) 0.4
BandWidth 14.24
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram 0.0004
Fundamentals Value
Market Cap 51.75 Million
Num Shares 43.5 Million
EPS -1.52
Price-to-Earnings (P/E) Ratio -0.78
Price-to-Sales 47.76
Price-to-Book 5.90
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.30
Resistance 3 (R3) 1.29 1.25 1.28
Resistance 2 (R2) 1.25 1.22 1.25 1.27
Resistance 1 (R1) 1.22 1.21 1.24 1.23 1.27
Pivot Point 1.18 1.18 1.19 1.18 1.18
Support 1 (S1) 1.15 1.15 1.17 1.16 1.11
Support 2 (S2) 1.11 1.14 1.11 1.11
Support 3 (S3) 1.08 1.11 1.10
Support 4 (S4) 1.09